Document is current
Any future updates will be listed below
-
Authors
Micheroli, Raphael https://orcid.org/0000-0002-8918-7304
Kissling, Seraphina https://orcid.org/0000-0003-0619-0012
Bürki, Kristina
Möller, Burkhard https://orcid.org/0000-0001-8769-6167
Finckh, Axel https://orcid.org/0000-0002-1210-4347
Nissen, Michael J. https://orcid.org/0000-0002-6326-1764
Exer, Pascale
Bräm, René
Kyburz, Diego https://orcid.org/0000-0002-9560-109X
Rubbert-Roth, Andrea
Andor, Michael
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
de Hooge, Manouk https://orcid.org/0000-0002-0652-9808
Distler, Oliver https://orcid.org/0000-0002-0546-8310
Scherer, Almut https://orcid.org/0000-0001-7382-4092
Ciurea, Adrian https://orcid.org/0000-0002-7870-7132
-
Funding
Funding for this research was provided by:
University of Zurich
- License Information
-
More Information
Article History
Received: 22 January 2023
Revised: 1 June 2023
Accepted: 1 June 2023
First Online: 8 June 2023
Declarations
:
: The study has been approved by the Ethics Commission of the Canton of Zurich (KEK-ZH-Nr. 2014–0439) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all patients.
: AC received honoraria for lectures from AbbVie and Novartis. AF received research grants to his institution from Abbvie, BMS, Galapagos, Eli Lilly and Pfizer, as well as consulting fees from Abbvie, AstraZeneca, BMS, Galapagos, Eli Lilly, Novartis, Merck Sharp & Dohme, Pfizer, Sandoz and Roche. ARR received honoraria for lectures and consultation from Abbvie, Amgen, BMS, UCB, Pfizer, Gilead, Eli Lilly, Novartis and Janssen. AS received consulting fees from Pfizer and support for attending meetings from Gilead. BM received speaking fees from Janssen, Eli Lilly, Novartis and Pfizer, support for attending meetings from Janssen and Pfizer and a research grant from Celgene. DK received consulting fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche and support for attending meetings from Janssen and Eli Lilly. MdH received grants from FWRO/FRSR and honoraria from UCB for participation in advisory board. MJN received consulting and/or speaking fees from Abbvie, Eli Lilly, Janssen, Novartis and Pfizer, as well as a research grant from Novartis. OD received consulting fees from Abbvie. PE received financial support from UCB for attending a meeting. RM received honoraria for lectures or presentations from Abbvie, Eli Lilly, Janssen, Gilead and Pfizer. KB, MA, RB, SK and XB declare they have no conflicts of interest.
